Paper Details

  1. Home
  2. Paper Details

Low-level night-time light therapy for age-related macular degeneration (ALight): study protocol for a randomized controlled trial.

Author: BaileyClare, BinnsAlison M, MargrainTom H, McKeagueClaire

Clinical Trial, Phase IThe first stage of clinical trials in humans. Evaluates the safety, tolerability, and pharmacokinetics of a new drug/treatment.
Clinical Trial, Phase IIA Phase II trial is a trial that further evaluates the efficacy and safety of a new drug or treatment, whose safety has been confirmed to some extent in a Phase I trial, in a small number of patients.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

Age-related macular degeneration (AMD) is a leading cause of blindness in older adults. This trial investigates the potential of a light mask emitting dim, green light during the night to prevent the progression of early AMD, based on the hypothesis that hypoxia plays a role in AMD development.
Paper Details　
Original Abstract of the Article :
Age-related macular degeneration (AMD) is the leading cause of blindness among older adults in the developed world. The only treatments currently available, such as ranibizumab injections, are for neovascular AMD, which accounts for only 10 to 15% of people with the condition. Hypoxia has been impli...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4227140/

データ提供：米国国立医学図書館（NLM）

Low-Level Night-Time Light Therapy: A Novel Approach for Age-Related Macular Degeneration (AMD)

Age-related macular degeneration (AMD) is a leading cause of vision loss in older adults. While there are treatments available for neovascular AMD, a specific subtype of the disease, there are currently no effective treatments for early AMD. This research proposes a novel approach to preventing the progression of early AMD: low-level night-time light therapy. The study proposes a randomized controlled trial to investigate whether wearing a light mask emitting dim green light during the night can reduce the risk of early AMD progression. The rationale behind this approach is that hypoxia, a condition of low oxygen levels, plays a key role in the development of AMD, and increasing light levels at night could potentially alleviate hypoxia and protect the retina.

Light Therapy: A Potential Game-Changer for AMD

This study represents a promising new avenue for exploring potential treatments for early AMD. Low-level night-time light therapy offers a non-invasive and potentially effective approach to preventing the progression of this vision-threatening condition. The results of this trial could have a significant impact on the management of AMD and potentially improve the lives of millions of people affected by this disease.

Navigating AMD: Exploring New Frontiers in Treatment

This research highlights the importance of exploring new and innovative approaches to managing AMD. Low-level night-time light therapy offers a potential game-changer for preventing the progression of early AMD, offering a glimmer of hope for individuals seeking to protect their vision.

Dr. Camel's Conclusion

The desert of age-related macular degeneration can be a daunting landscape, filled with the threat of vision loss. This research offers a potential oasis in this dry and unforgiving terrain. Low-level night-time light therapy represents a promising new path toward preventing the progression of early AMD, potentially restoring the clarity of vision for many. Let's continue to explore innovative approaches and discover new ways to protect our precious sense of sight, ensuring that we can continue to navigate the world with clarity and joy.

Date :
  1. Date Completed 2015-03-31
  2. Date Revised 2021-10-21
Further Info :

Pubmed ID

24965385

DOI: Digital Object Identifier

PMC4227140

Related Literature

Article Analysis
・Effective treatment of macular degeneration
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.